Naurex Inc. is a pharmaceutical company which is developing the drug candidates rapastinel (GLYX-13) and NRX-1074, NMDA receptor modulators, as novel, next-generation antidepressants.
On July 26, 2015, it was announced that Allergan would be acquiring Naurex for $560 million.
